In-vitro Transcription Templates Market

In-vitro Transcription Templates Market (Disease: Cancer, Infectious Diseases, Lifestyle Diseases, Genetic Diseases, and Others; and Treatment: Vaccine and Therapeutic) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global In-vitro Transcription Templates Market Outlook 2031

  • The industry was valued at US$ 231.6 Mn in 2022
  • It is estimated to advance at a CAGR of 20.0% from 2023 to 2031 and reach US$ 1.2 Bn by the end of 2031

Analyst Viewpoint

Rise in prevalence of infectious diseases and increase in investments in R&D in healthcare and pharmaceutical sectors are fostering the in-vitro transcription templates market size. The in-vitro transcription process allows the design of RNA structure and the templates are extensively used in drug development for various diseases.

Rise in prevalence of chronic conditions among the population is fueling market expansion.

Emergence of severe infectious diseases and developments biotechnology sector offers lucrative in-vitro transcription templates market opportunities to the players operating in this sector. Key players in the market focus on business expansion through partnerships to expand their global reach.

Moreover, new product launches and innovation in existing product ranges allow companies to enhance their product portfolio.

Market Introduction

In-vitro transcription is a technique commonly used in molecular biology research to produce RNA molecules for various purposes, such as studying gene expression, RNA structure-function relationships, RNA-protein interactions, and RNA-based therapeutics.

In-vitro transcription templates are DNA sequences that serve as templates for the synthesis of RNA molecules in a laboratory setting, outside of a living organism. Optimized in-vitro transcription templates are utilized in the pharmaceutical & biotechnology sector to ensure accuracy and efficiency.

Design and preparation of DNA templates, template amplification, transcription reaction, RNA purification, and characterization and analysis are crucial steps involved in the in-vitro transcription process. In-vitro transcription matrices are used in algorithms for predicting or modeling transcription factor binding sites on DNA sequences.

In-vitro transcription primer sequences can be utilized, particularly in techniques including Reverse Transcription (RT) before in-vitro transcription or in generating templates by PCR amplification. The specific primer sequences would depend on experimental design and intended use of the RNA transcripts.

Rise in Prevalence of Infectious Diseases Fostering In-vitro Transcription Templates Market Growth

In-vitro transcription templates play a crucial role in the development of vaccines against infectious diseases. Increase in environmental concerns and the spread of bacteria are leading causes of infectious diseases.

In-vitro transcription templates can be used to generate RNA molecules encoding specific antigens, which can then be used in various assays, such as Enzyme-Linked Immunosorbent Assays (ELISA) or lateral flow assays, for the detection of infectious agents or development of serological tests to detect antibodies against them.

Thus, rise in prevalence of infectious diseases is fueling the in-vitro transcription templates market value.Neurological diseases, chronic kidney diseases, and cancer are some of the leading health concerns among the population.

In-vitro transcription templates are employed in various procedures, including gene expression studies, RNA structural studies, biomarker discovery, drug target identification, oncogene expression studies, diagnostic marker development, and RNA-based therapeutics. Hence, increase in the number of chronic kidney disease cases is propelling market statistics.

Increase in Investments in R&D in Healthcare and Pharmaceutical Sectors Propelling Market Dynamics

Pharmaceutical and biotechnology companies invest in research and development activities to introduce advanced treatments and therapies for various diseases.

Organizations in the pharmaceutical and healthcare industries focus on template design and engineering, enhanced transcription efficiency, synthetic biology applications, high-throughput screening, RNA engineering and modification, and therapeutic applications to provide effective treatments for chronic diseases.

Thus, rise in investments in R&D in healthcare and pharmaceutical sectors is contributing to the in-vitro transcription templates industry growth.

RNA transcript precursors are the initial transcripts synthesized by RNA polymerase during transcription in eukaryotic cells. These precursors undergo several post-transcriptional processing steps to mature into functional mRNA molecules that can be translated into proteins.

Increase in drug development practices for chronic diseases is fostering the in-vitro transcription templates market development. Hence, rise in prevalence of chronic diseases is propelling market progress.

According to the World Health Organization, Noncommunicable Diseases (NCDs) account for around 41 million fatalities each year, equivalent to 74% of all deaths across the globe.

Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million including kidney disease deaths caused by diabetes).

Regional Outlook

As per the latest in-vitro transcription templates market analysis, Asia Pacific dominated the global market in 2022. Rise in demand for biopharmaceuticals, such as RNA-based therapeutics, vaccines, and peptides for various treatments is likely to propel the in-vitro transcription templates industry share during the forecast period.

Well-established healthcare infrastructure and increase in investments in drug development for infectious diseases are augmenting market dynamics.

Moreover, government funding for the expansion of research institutes and providing advanced healthcare facilities are supporting the market growth. Rise in prevalence of infectious diseases, such as COVID-19 is driving the demand for in-vitro transcription templates for vaccine development.

Analysis of Key Players in In-vitro Transcription Templates Industry

As per the recent in-vitro transcription templates market trends, advancements in drug development technologies offer lucrative opportunities to the companies operating in this industry.

Leading players in the market are focusing on business expansion to enhance their product portfolio and increase their global brand presence. They are investing in innovation and new product launches to meet consumer demands.

Some of the players in the industry are Thermo Fisher Scientific Inc., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Takara Bio Inc., LGC Limited, Enzynomics Co. Ltd., Enzo Life Sciences, Inc., and Danaher Corporation.

These companies have been profiled in the in-vitro transcription templates market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.

Key Developments

  • In December 2023, BioLabs, an innovative healthcare company expert in manufacturing and quality control of high-end pharmaceutical products, and Promega Corporation, a worldwide leader in applying biochemistry and molecular biology, announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies. Promega GmbH in Walldorf, the German branch of global life science manufacturer Promega, will provide equipment, services, and training to BioLabs Heidelberg.
  • In October 2023, Vernal Biosciences, a leading Contract Development and Manufacturing Organization (CDMO) specializing in mRNA and LNP manufacturing, participated in the 11th International mRNA Health Conference held in Berlin. Vernal Biosciences unveiled three groundbreaking posters that highlight innovative advancements in mRNA technologies and the flexibility of Vernal’s platform process technologies.

In-vitro Transcription Templates Market Snapshot

Attribute Detail
Market Size in 2022 US$ 231.6 Mn
Market Forecast (Value) in 2031 US$ 1.2 Bn
Growth Rate (CAGR) 20.0%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Tons US$ Bn/Mn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Disease
    • Cancer
      • Solid Tumors
      • Colorectal Cancer
      • NSCLC
      • Melanoma
      • Leukemia
      • Prostate Cancer
      • Others
    • Infectious Diseases
      • Influenza
      • COVID-19
      • AIDS
      • Others
    • Lifestyle Diseases
    • Genetic Diseases
    • Others
  • Treatment
    • Vaccine
    • Therapeutic
  • Research Stage
    • Exploratory
    • Clinical
  • End-user
    • Pharmaceutical & Biotechnology Companies
    • CROs & CMOs
    • Academics & Research
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC countries
Companies Profiled
  • Thermo Fisher Scientific Inc.
  • Promega Corporation
  • Agilent Technologies, Inc.
  • New England Biolabs
  • Takara Bio Inc.
  • LGC Limited
  • Enzynomics Co. Ltd.
  • Enzo Life Sciences, Inc.
  • Danaher Corporation
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global in-vitro transcription templates market in 2022?

It was valued at US$ 231.6 Mn in 2022

How is the in-vitro transcription templates sector expected to grow by 2031?

It is projected to register a CAGR of 20.0% from 2023 to 2031

What are the key factors driving the demand for in-vitro transcription templates?

Rise in prevalence of infectious diseases and increase in investments in R&D in healthcare and pharmaceutical sectors

Which was the most lucrative region in the in-vitro transcription templates industry in 2022?

Asia Pacific was the most lucrative region in 2022

Who are the prominent vendors in the in-vitro transcription templates business?

Thermo Fisher Scientific Inc., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Takara Bio Inc., LGC Limited, Enzynomics Co. Ltd., Enzo Life Sciences, Inc., and Danaher Corporation.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global In-vitro Transcription Templates Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global In-vitro Transcription Templates Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global In-vitro Transcription Templates Market Analysis and Forecast, by Disease

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Disease, 2017–2031

            6.3.1. Cancer

                6.3.1.1. Solid Tumors

                6.3.1.2. Colorectal Cancer

                6.3.1.3. NSCLC

                6.3.1.4. Melanoma

                6.3.1.5. Leukemia

                6.3.1.6. Prostate Cancer

                6.3.1.7. Others

            6.3.2. Infectious Diseases

                6.3.2.1. Influenza

                6.3.2.2. COVID-19

                6.3.2.3. AIDS

                6.3.2.4. Others

            6.3.3. Lifestyle Diseases

            6.3.4. Genetic Diseases

            6.3.5. Others

        6.4. Market Attractiveness, by Disease

    7. Global In-vitro Transcription Templates Market Analysis and Forecast, by Treatment

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Treatment, 2017–2031

            7.3.1. Vaccine

            7.3.2. Therapeutic

            7.3.3. 7.4 Market Attractiveness, by Treatment

    8. Global In-vitro Transcription Templates Market Analysis and Forecast, by Research Stage

        8.1. Introduction and Definitions

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Research Stage, 2017–2031

            8.3.1. Exploratory

            8.3.2. Clinical

        8.4. Market Attractiveness, by Research Stage

    9. Global In-vitro Transcription Templates Market Analysis and Forecast, by End-user

        9.1. Introduction and Definitions

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by End-user, 2017–2031

            9.3.1. Pharmaceutical & Biotechnology Companies

            9.3.2. CROs & CMOs

            9.3.3. Academics & Research

            9.3.4. Others

        9.4. Market Attractiveness, by End-user

    10. Global In-vitro Transcription Templates Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region, 2017–2031

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness, by Region

    11. North America In-vitro Transcription Templates Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Disease, 2017–2031

            11.2.1. Cancer

                11.2.1.1. Solid Tumors

                11.2.1.2. Colorectal Cancer

                11.2.1.3. NSCLC

                11.2.1.4. Melanoma

                11.2.1.5. Leukemia

                11.2.1.6. Prostate Cancer

                11.2.1.7. Others

            11.2.2. Infectious Diseases

                11.2.2.1. Influenza

                11.2.2.2. COVID-19

                11.2.2.3. AIDS

                11.2.2.4. Others

            11.2.3. Lifestyle Diseases

            11.2.4. Genetic Diseases

            11.2.5. Others

        11.3. Market Attractiveness, by Disease

        11.4. Market Value Forecast, by Treatment, 2017–2031

            11.4.1. Vaccine

            11.4.2. Therapeutic

        11.5. Market Attractiveness, by Treatment

        11.6. Market Value Forecast, by Research Stage, 2017–2031

            11.6.1. Exploratory

            11.6.2. Clinical

        11.7. Market Attractiveness, by Research Stage

        11.8. Market Value Forecast, by End-user, 2017–2031

            11.8.1. Pharmaceutical & Biotechnology Companies

            11.8.2. CROs & CMOs

            11.8.3. Academics & Research

            11.8.4. Others

        11.9. Market Attractiveness, by End-user

        11.10. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.10.1. U.S.

            11.10.2. Canada

        11.11. Market Attractiveness Analysis

            11.11.1. By Disease

            11.11.2. By Treatment

            11.11.3. By Research Stage

            11.11.4. By End-user

            11.11.5. By Country

    12. Europe In-vitro Transcription Templates Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Disease, 2017–2031

            12.2.1. Cancer

                12.2.1.1. Solid Tumors

                12.2.1.2. Colorectal Cancer

                12.2.1.3. NSCLC

                12.2.1.4. Melanoma

                12.2.1.5. Leukemia

                12.2.1.6. Prostate Cancer

                12.2.1.7. Others

            12.2.2. Infectious Diseases

                12.2.2.1. Influenza

                12.2.2.2. COVID-19

                12.2.2.3. AIDS

                12.2.2.4. Others

            12.2.3. Lifestyle Diseases

            12.2.4. Genetic Diseases

            12.2.5. Others

        12.3. Market Attractiveness, by Disease

        12.4. Market Value Forecast, by Treatment, 2017–2031

            12.4.1. Vaccine

            12.4.2. Therapeutic

        12.5. Market Attractiveness, by Treatment

        12.6. Market Value Forecast, by Research Stage, 2017–2031

            12.6.1. Exploratory

            12.6.2. Clinical

        12.7. Market Attractiveness, by Research Stage

        12.8. Market Value Forecast, by End-user, 2017–2031

            12.8.1. Pharmaceutical & Biotechnology Companies

            12.8.2. CROs & CMOs

            12.8.3. Academics & Research

            12.8.4. Others

        12.9. Market Attractiveness, by End-user

        12.10. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.10.1. Germany

            12.10.2. U.K.

            12.10.3. France

            12.10.4. Italy

            12.10.5. Spain

            12.10.6. Rest of Europe

        12.11. Market Attractiveness Analysis

            12.11.1. By Disease

            12.11.2. By Treatment

            12.11.3. By Research Stage

            12.11.4. By End-user

            12.11.5. By Country/Sub-region

    13. Asia Pacific In-vitro Transcription Templates Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Disease, 2017–2031

            13.2.1. Cancer

                13.2.1.1. Solid Tumors

                13.2.1.2. Colorectal Cancer

                13.2.1.3. NSCLC

                13.2.1.4. Melanoma

                13.2.1.5. Leukemia

                13.2.1.6. Prostate Cancer

                13.2.1.7. Others

            13.2.2. Infectious Diseases

                13.2.2.1. Influenza

                13.2.2.2. COVID-19

                13.2.2.3. AIDS

                13.2.2.4. Others

            13.2.3. Lifestyle Diseases

            13.2.4. Genetic Diseases

            13.2.5. Others

        13.3. Market Attractiveness, by Disease

        13.4. Market Value Forecast, by Treatment, 2017–2031

            13.4.1. Vaccine

            13.4.2. Therapeutic

        13.5. Market Attractiveness, by Treatment

        13.6. Market Value Forecast, by Research Stage, 2017–2031

            13.6.1. Exploratory

            13.6.2. Clinical

        13.7. Market Attractiveness, by Research Stage

        13.8. Market Value Forecast, by End-user, 2017–2031

            13.8.1. Pharmaceutical & Biotechnology Companies

            13.8.2. CROs & CMOs

            13.8.3. Academics & Research

            13.8.4. Others

        13.9. Market Attractiveness, by End-user

        13.10. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.10.1. China

            13.10.2. Japan

            13.10.3. India

            13.10.4. Australia & New Zealand

            13.10.5. Rest of Asia Pacific

        13.11. Market Attractiveness Analysis

            13.11.1. By Disease

            13.11.2. By Treatment

            13.11.3. By Research Stage

            13.11.4. By End-user

            13.11.5. By Country/Sub-region

    14. Latin America In-vitro Transcription Templates Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Disease, 2017–2031

            14.2.1. Cancer

                14.2.1.1. Solid Tumors

                14.2.1.2. Colorectal Cancer

                14.2.1.3. NSCLC

                14.2.1.4. Melanoma

                14.2.1.5. Leukemia

                14.2.1.6. Prostate Cancer

                14.2.1.7. Others

            14.2.2. Infectious Diseases

                14.2.2.1. Influenza

                14.2.2.2. COVID-19

                14.2.2.3. AIDS

                14.2.2.4. Others

            14.2.3. Lifestyle Diseases

            14.2.4. Genetic Diseases

            14.2.5. Others

        14.3. Market Attractiveness, by Disease

        14.4. Market Value Forecast, by Treatment, 2017–2031

            14.4.1. Vaccine

            14.4.2. Therapeutic

        14.5. Market Attractiveness, by Treatment

        14.6. Market Value Forecast, by Research Stage, 2017–2031

            14.6.1. Exploratory

            14.6.2. Clinical

        14.7. Market Attractiveness, by Research Stage

        14.8. Market Value Forecast, by End-user, 2017–2031

            14.8.1. Pharmaceutical & Biotechnology Companies

            14.8.2. CROs & CMOs

            14.8.3. Academics & Research

            14.8.4. Others

        14.9. Market Attractiveness, by End-user

        14.10. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.10.1. Brazil

            14.10.2. Mexico

            14.10.3. Rest of Latin America

        14.11. Market Attractiveness Analysis

            14.11.1. By Disease

            14.11.2. By Treatment

            14.11.3. By Research Stage

            14.11.4. By End-user

            14.11.5. By Country/Sub-region

    15. Middle East & Africa In-vitro Transcription Templates Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Disease, 2017–2031

            15.2.1. Cancer

                15.2.1.1. Solid Tumors

                15.2.1.2. Colorectal Cancer

                15.2.1.3. NSCLC

                15.2.1.4. Melanoma

                15.2.1.5. Leukemia

                15.2.1.6. Prostate Cancer

                15.2.1.7. Others

            15.2.2. Infectious Diseases

                15.2.2.1. Influenza

                15.2.2.2. COVID-19

                15.2.2.3. AIDS

                15.2.2.4. Others

            15.2.3. Lifestyle Diseases

            15.2.4. Genetic Diseases

            15.2.5. Others

        15.3. Market Attractiveness, by Disease

        15.4. Market Value Forecast, by Treatment, 2017–2031

            15.4.1. Vaccine

            15.4.2. Therapeutic

        15.5. Market Attractiveness, by Treatment

        15.6. Market Value Forecast, by Research Stage, 2017–2031

            15.6.1. Exploratory

            15.6.2. Clinical

        15.7. Market Attractiveness, by Research Stage

        15.8. Market Value Forecast, by End-user, 2017–2031

            15.8.1. Pharmaceutical & Biotechnology Companies

            15.8.2. CROs & CMOs

            15.8.3. Academics & Research

            15.8.4. Others

        15.9. Market Attractiveness, by End-user

        15.10. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.10.1. GCC Countries

            15.10.2. South Africa

            15.10.3. Rest of Middle East & Africa

        15.11. Market Attractiveness Analysis

            15.11.1. By Disease

            15.11.2. By Treatment

            15.11.3. By Research Stage

            15.11.4. By End-user

            15.11.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        16.2. Market Share Analysis, by Company (2022)

        16.3. Company Profiles

            16.3.1. Thermo Fisher Scientific Inc.

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Promega Corporation

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. Agilent Technologies, Inc.

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. New England Biolabs

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Takara Bio Inc.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. LGC Limited

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. Enzynomics Co. Ltd.

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Enzo Life Sciences, Inc.

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. Danaher Corporation

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 02: Global In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 03: Global In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Global In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Research Stage, 2017–2031

    Table 05: Global In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 08: North America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 9: North America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Research Stage, 2017–2031

    Table 10: North America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 11: Europe In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 12: Europe In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 13: Europe In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 14: Europe In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Research Stage, 2017–2031

    Table 15: Europe In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 16: Asia Pacific In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 18: Asia Pacific In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 19: Asia Pacific In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Research Stage, 2017–2031

    Table 20: Asia Pacific In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 21: Latin America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Latin America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 23: Latin America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 24: Latin America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Research Stage, 2017–2031

    Table 25: Latin America In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 26: Middle East & Africa In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 27: Middle East & Africa In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 28: Middle East & Africa In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 29: Middle East & Africa In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by Research Stage, 2017–2031

    Table 30: Middle East & Africa In-vitro Transcription Templates Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global In-vitro Transcription Templates Market Size (US$ Mn), by Region, 2022–2031

    Figure 02: Global In-vitro Transcription Templates Market Revenue (US$ Mn), by Disease, 2022

    Figure 03: Global In-vitro Transcription Templates Market Value Share, by Disease, 2022

    Figure 04: Global In-vitro Transcription Templates Market Revenue (US$ Mn), by Treatment, 2022

    Figure 05: Global In-vitro Transcription Templates Market Value Share, by Treatment, 2022

    Figure 06: Global In-vitro Transcription Templates Market Revenue (US$ Mn), by Research Stage, 2022

    Figure 07: Global In-vitro Transcription Templates Market Value Share, by Research Stage, 2022

    Figure 08: Global In-vitro Transcription Templates Market Revenue (US$ Mn), by End-user, 2022

    Figure 09: Global In-vitro Transcription Templates Market Value Share, by End-user, 2022

    Figure 10: Global In-vitro Transcription Templates Market Value Share, by Region, 2022

    Figure 11: Global In-vitro Transcription Templates Market Value (US$ Mn) Forecast, 2017–2031

    Figure 12: Global In-vitro Transcription Templates Market Value Share Analysis, by Disease, 2022–2031

    Figure 13: Global In-vitro Transcription Templates Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 14: Global In-vitro Transcription Templates Market Value Share Analysis, by Treatment, 2022–2031

    Figure 15: Global In-vitro Transcription Templates Market Attractiveness Analysis, by Treatment, 2023–2031

    Figure 16: Global In-vitro Transcription Templates Market Value Share Analysis, by Research Stage, 2022–2031

    Figure 17: Global In-vitro Transcription Templates Market Attractiveness Analysis, by Research Stage, 2023–2031

    Figure 18: Global In-vitro Transcription Templates Market Revenue (US$ Mn), by End-user, 2022

    Figure 19: Global In-vitro Transcription Templates Market Value Share, by End-user, 2022

    Figure 20: Global In-vitro Transcription Templates Market Value Share Analysis, by Region, 2022–2031

    Figure 21: Global In-vitro Transcription Templates Market Attractiveness Analysis, by Region, 2023–2031

    Figure 22: North America In-vitro Transcription Templates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 23: North America In-vitro Transcription Templates Market Attractiveness Analysis, by Country, 2023–2031

    Figure 24: North America In-vitro Transcription Templates Market Value Share Analysis, by Country, 2022–2031

    Figure 25: North America In-vitro Transcription Templates Market Value Share Analysis, by Disease, 2022–2031

    Figure 26: North America In-vitro Transcription Templates Market Value Share Analysis, by Treatment, 2022–2031

    Figure 27: North America In-vitro Transcription Templates Market Value Share Analysis, by Research Stage, 2022–2031

    Figure 28: North America In-vitro Transcription Templates Market Value Share Analysis, by End-user, 2022–2031

    Figure 29: North America In-vitro Transcription Templates Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 30: North America In-vitro Transcription Templates Market Attractiveness Analysis, by Treatment, 2023–2031

    Figure 31: North America In-vitro Transcription Templates Market Attractiveness Analysis, by Research Stage, 2023–2031

    Figure 32: North America In-vitro Transcription Templates Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 33: Europe In-vitro Transcription Templates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 34: Europe In-vitro Transcription Templates Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 35: Europe In-vitro Transcription Templates Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 36: Europe In-vitro Transcription Templates Market Value Share Analysis, by Disease, 2022–2031

    Figure 37: Europe In-vitro Transcription Templates Market Value Share Analysis, by Treatment, 2022–2031

    Figure 38: Europe In-vitro Transcription Templates Market Value Share Analysis, by Research Stage, 2022–2031

    Figure 39: Europe In-vitro Transcription Templates Market Value Share Analysis, by End-user, 2022–2031

    Figure 40: Europe In-vitro Transcription Templates Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 41: Europe In-vitro Transcription Templates Market Attractiveness Analysis, by Treatment, 2023–2031

    Figure 42: Europe In-vitro Transcription Templates Market Attractiveness Analysis, by Research Stage, 2023–2031

    Figure 43: Europe In-vitro Transcription Templates Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 44: Asia Pacific In-vitro Transcription Templates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 45: Asia Pacific In-vitro Transcription Templates Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 46: Asia Pacific In-vitro Transcription Templates Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 47: Asia Pacific In-vitro Transcription Templates Market Value Share Analysis, by Disease, 2022–2031

    Figure 48: Asia Pacific In-vitro Transcription Templates Market Value Share Analysis, by Treatment, 2022–2031

    Figure 49: Asia Pacific In-vitro Transcription Templates Market Value Share Analysis, by Research Stage, 2022–2031

    Figure 50: Asia Pacific In-vitro Transcription Templates Market Value Share Analysis, by End-user, 2022–2031

    Figure 51: Asia Pacific In-vitro Transcription Templates Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 52: Asia Pacific In-vitro Transcription Templates Market Attractiveness Analysis, by Treatment, 2023–2031

    Figure 53: Asia Pacific In-vitro Transcription Templates Market Attractiveness Analysis, by Research Stage, 2023–2031

    Figure 54: Asia Pacific In-vitro Transcription Templates Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 55: Latin America In-vitro Transcription Templates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 56: Latin America In-vitro Transcription Templates Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 57: Latin America In-vitro Transcription Templates Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 58: Latin America In-vitro Transcription Templates Market Value Share Analysis, by Disease, 2022–2031

    Figure 59: Latin America In-vitro Transcription Templates Market Value Share Analysis, by Treatment, 2022–2031

    Figure 60: Latin America In-vitro Transcription Templates Market Value Share Analysis, by Research Stage, 2022–2031

    Figure 61: Latin America In-vitro Transcription Templates Market Value Share Analysis, by End-user, 2022–2031

    Figure 62: Latin America In-vitro Transcription Templates Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 63: Latin America In-vitro Transcription Templates Market Attractiveness Analysis, by Treatment, 2023–2031

    Figure 64: Latin America In-vitro Transcription Templates Market Attractiveness Analysis, by Research Stage, 2023–2031

    Figure 65: Latin America In-vitro Transcription Templates Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 66: Middle East & Africa In-vitro Transcription Templates Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 67: Middle East & Africa In-vitro Transcription Templates Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 68: Middle East & Africa In-vitro Transcription Templates Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 69: Middle East & Africa In-vitro Transcription Templates Market Value Share Analysis, by Disease, 2022–2031

    Figure 70: Middle East & Africa In-vitro Transcription Templates Market Value Share Analysis, by Treatment, 2022–2031

    Figure 71: Middle East & Africa In-vitro Transcription Templates Market Value Share Analysis, by Research Stage, 2022–2031

    Figure 72: Middle East & Africa In-vitro Transcription Templates Market Value Share Analysis, by End-user, 2022–2031

    Figure 73: Middle East & Africa In-vitro Transcription Templates Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 74: Middle East & Africa In-vitro Transcription Templates Market Attractiveness Analysis, by Treatment, 2023–2031

    Figure 75: Middle East & Africa In-vitro Transcription Templates Market Attractiveness Analysis, by Research Stage, 2023–2031

    Figure 76: Middle East & Africa In-vitro Transcription Templates Market Attractiveness Analysis, by End-user, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved